Insights into medicinal attributes of imidazo[1,2‐ a ]pyridine derivatives as anticancer agents
Archiv der Pharmazie · 2024
DOI: 10.1002/ardp.202400402 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Archiv der Pharmazie, 2024. Verfasst von Ankush Kumar und 9 weiteren Autor:innen. Beteiligte Einrichtung: Amity School of Pharmaceutical Sciences, Amity University, Mohali, Punjab, India. Hauptthemen laut MEDLINE: Antineoplastic Agents, Pyridines, Imidazoles. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 92 Literaturangaben.
Abstract (Originalsprache)
Cancer ranks among the most life‐threatening diseases worldwide and is continuously affecting all age groups. Consequently, many research studies are being carried out to develop new cancer treatments, but many of them experience resistance and cause severe toxicity to the patients. Therefore, there is a continuous need to design novel anticancer agents that are target‐based, have a higher potency, and have minimal toxicity. The imidazo[1,2‐ a ]pyridine (IP) pharmacophore has been found to be a prominent moiety in the field of medicinal chemistry due to its vast biological properties. Also, it holds immense potential for combating cancer with minimal side effects, depending on the substitution patterns of the core structure. IPs exhibit significant capability in regulating various cellular pathways, offering possibilities for targeted anticancer effects. The present review summarizes the anticancer profile of numerous IP derivatives synthesized and developed by various researchers from 2016 till now, as inhibitors of phosphoinositide‐3‐kinase/mammalian target of rapamycin (PI3K/mTOR), protein kinase B/mammalian target of rapamycin (Akt/mTOR), aldehyde dehydrogenase (ALDH), and tubulin polymerization. This review provides a comprehensive analysis of the anticancer activity afforded by the discussed IP compounds, emphasizing the structure–activity‐relationships (SARs). The aim is also to underscore the potential therapeutic future of the IP moiety as a potent partial structure for upcoming cancer drug development and to aid researchers in the field of rational drug design.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Amity School of Pharmaceutical Sciences, Amity University, Mohali, Punjab, India.
- Department of Chemistry and Biochemistry, School of Sciences, JAIN (Deemed to be University), Bangalore, Karnataka, India.
- Department of Pharmacy Practice, Institute of Pharmacy, NIMS University, Jaipur, Rajasthan, India.
- School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, India.
- ARCCIM, Faculty of Health, University of Technology Sydney, Ultimo, Sydney, New South Wales, Australia.
- Department of Pharmacognosy, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj, Saudi Arabia.
Zitieren
APA
Kumar, A., Sharma, V., Behl, T., Ganesan, S., Nathiya, D., Gulati, M., Khalid, M., Elossaily, G. M., Chigurupati, S., & Sachdeva, M. (2024). Insights into medicinal attributes of imidazo[1,2‐ a ]pyridine derivatives as anticancer agents. Archiv der Pharmazie. https://doi.org/10.1002/ardp.202400402
Vancouver
Kumar A, Sharma V, Behl T, Ganesan S, Nathiya D, Gulati M, et al. Insights into medicinal attributes of imidazo[1,2‐ a ]pyridine derivatives as anticancer agents. Archiv der Pharmazie. 2024. doi:10.1002/ardp.202400402
BibTeX
@article{Kumar2024,
author = {Kumar, Ankush and Sharma, Vishakha and Behl, Tapan and Ganesan, Subbulakshmi and Nathiya, Deepak and Gulati, Monica and Khalid, Mohammad and Elossaily, Gehan M and Chigurupati, Sridevi and Sachdeva, Monika},
title = {Insights into medicinal attributes of imidazo[1,2‐ a ]pyridine derivatives as anticancer agents},
journal = {Archiv der Pharmazie},
year = {2024},
doi = {10.1002/ardp.202400402}
}
EUVIMED